Payment overview · 2025
General Payments
$646.97
36 reported records · 13 companies
Healthcare provider profile · identity verified
Eugene A. Cullen, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBIA, NJ · NPI 1487620407
Verified facts
What the public records show
CMS Open Payments records show Eugene A. Cullen, M.D. received $646.97 in general payments during 2025 across 36 reported records.
Amgen Inc. accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.94 | 12.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.05 | 12.4% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $64.80 | 10.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.03 | 9.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.55 | 8.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.27 | 7.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.44 | 7.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.77 | 6.9% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.07 | 6.7% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.62 | 6.0% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $33.31 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.49 | 4.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.63 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $646.97 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.94 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.94 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $64.80 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $61.03 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $51.55 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $51.27 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.69 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.69 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.69 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $43.07 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.36 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $33.31 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.49 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.49 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.27 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.63 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
44 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 581 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 387 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 360 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 89 |
| Alprazolam | Alprazolam | 306 | 64 |
| Lisinopril | Lisinopril | 299 | 73 |
| Prednisone | Prednisone | 280 | 138 |
| Metformin Hcl | Metformin Hcl | 233 | 67 |
| Doxycycline Hyclate | Doxycycline Hyclate | 220 | 152 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 70 |
| Potassium Chloride | Potassium Chloride | 213 | 59 |
| Azithromycin | Azithromycin | 209 | 156 |
| Valsartan | Valsartan | 172 | 47 |
| Gabapentin | Gabapentin | 167 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 155 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 138 | 95 |
| Cefuroxime | Cefuroxime Axetil | 135 | 107 |
| Benazepril Hcl | Benazepril Hcl | 134 | 36 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 128 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 34 |
| Furosemide | Furosemide | 121 | 33 |
| Lorazepam | Lorazepam | 119 | 22 |
| Ozempic | Semaglutide | 118 | 17 |
| Simvastatin | Simvastatin | 112 | 31 |
| Tramadol Hcl | Tramadol Hcl | 111 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 33 |
| Carvedilol | Carvedilol | 105 | 29 |
| Glipizide Er | Glipizide | 105 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 29 |
| Sertraline Hcl | Sertraline Hcl | 101 | 28 |
| Allopurinol | Allopurinol | 98 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 39 |
| Trazodone Hcl | Trazodone Hcl | 94 | 28 |
| Atenolol | Atenolol | 89 | 24 |
| Montelukast Sodium | Montelukast Sodium | 88 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 22 |
| Losartan Potassium | Losartan Potassium | 84 | 27 |
| Omeprazole | Omeprazole | 84 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 79 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 79 | 53 |
| Eliquis | Apixaban | 74 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 12 |
| Donepezil Hcl | Donepezil Hcl | 71 | 18 |
| Clindamycin Hcl | Clindamycin Hcl | 68 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 21 |
| Mounjaro | Tirzepatide | 67 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 38 |
| Cefdinir | Cefdinir | 62 | 44 |
| Clonazepam | Clonazepam | 59 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Synthroid | Levothyroxine Sodium | 58 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 44 |
| Finasteride | Finasteride | 56 | 17 |
| Jardiance | Empagliflozin | 55 | 15 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 52 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Fenofibrate | Fenofibrate | 51 | 12 |
| Meclizine Hcl | Meclizine Hcl | 51 | 20 |
| Sucralfate | Sucralfate | 51 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Ezetimibe | Ezetimibe | 46 | 15 |
| Valacyclovir | Valacyclovir Hcl | 46 | 26 |
| Amoxicillin | Amoxicillin | 44 | 38 |
| Famotidine | Famotidine | 44 | 18 |
| Fluconazole | Fluconazole | 44 | 32 |
| Memantine Hcl | Memantine Hcl | 44 | 12 |
| Metformin Hcl Er | Metformin Hcl | 44 | 17 |
| Nystatin | Nystatin | 44 | 21 |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 44 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Irbesartan | Irbesartan | 42 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Torsemide | Torsemide | 39 | 12 |
| Diazepam | Diazepam | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 14 |
| Ondansetron Odt | Ondansetron | 37 | 19 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Mupirocin | Mupirocin | 34 | 17 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Ssd | Silver Sulfadiazine | 28 | 22 |
| Baclofen | Baclofen | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Epinephrine | Epinephrine | 20 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fluocinonide | Fluocinonide | 19 | 15 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Lactulose | Lactulose | 18 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 16 |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 15 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Atovaquone | Atovaquone | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Cefadroxil | Cefadroxil | 13 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Clarithromycin | Clarithromycin | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $646.97 · 36 records | Amgen Inc. | ABRYSVO, AREXVY, BREZTRI, COMIRNATY, ELIQUIS, FARXIGA, GIVLAARI, JARDIANCE, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, PREVNAR 20, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error